On December 5, 2023, James F. Polewaczyk, Executive Vice President and Chief Commercial Officer of IDEXX Laboratories, Inc. (the ?Company?), notified the Company of his intent to retire after more than 17 years of dedicated leadership and service, effective April 1, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
548.5 USD | +5.26% | +12.62% | -1.17% |
May. 14 | Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $596 From $620 | MT |
May. 02 | BNP Paribas Adjusts Price Target on IDEXX Laboratories to $641 From $653 | MT |
EPS Revisions
- Stock Market
- Equities
- IDXX Stock
- News IDEXX Laboratories, Inc.
- IDEXX Laboratories, Inc. Announces Retirement of James F. Polewaczyk, Executive Vice President and Chief Commercial Officer, Effective April 1, 2024